Invenomic Capital Management’s Bausch Health BHC Stock Holding History

Invenomic Capital Management’s Portfolio BHC Stock Details BHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-288,964	Closed	-$5.27M	–	150
2022 Q1	$5.27M	Buy	288,964 +137,666	+91%	+$3.36M	0.56%	55
2021 Q4	$4.18M	Buy	151,298 +19,902	+15%	+$533K	0.89%	41
2021 Q3	$3.66M	Sell	131,396 -10,167	-7%	-$288K	1.19%	30
2021 Q2	$4.15M	Sell	141,563 -25,073	-15%	-$760K	0.99%	20
2021 Q1	$5.29M	Buy	166,636 +31,941	+24%	+$937K	1.18%	12
2020 Q4	$2.8M	Sell	134,695 -45,169	-25%	-$843K	0.71%	24
2020 Q3	$2.79M	Buy	179,864 +52,633	+41%	+$907K	1.54%	12
2020 Q2	$2.33M	Buy	127,231 +32,190	+34%	+$567K	1.72%	10
2020 Q1	$1.47M	Sell	95,041 -172,699	-65%	-$4.16M	1.2%	27
2019 Q4	$8.01M	Buy	+267,740	New	+$6.96M	3.22%	1

Other funds holding BHC

Icahn Carl Sunny Isles Beach, Florida $8.26B AUM 15.11% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ValueAct Holdings San Francisco, California $5.63B AUM 5.11% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Invenomic Capital Management's BHC Position: Q2 2022 in Review

Invenomic Capital Management sold out of Bausch Health (BHC) in Q2 2022, closing a stake of 288,964 shares — an estimated $5.27M sold.

Invenomic Capital Management first reported a position in BHC in Q4 2019 and held it in 10 quarters. The position peaked at $8.01M in Q4 2019. 327 funds tracked by Wall St. Rank hold BHC as of Q2 2022.

Invenomic Capital Management reported no remaining Bausch Health position as of Q2 2022 after selling out during the quarter.
Invenomic Capital Management sold 288,964 Bausch Health shares in Q2 2022, an estimated $5.27M.
Invenomic Capital Management first reported a position in Bausch Health in Q4 2019 and held it in 10 quarters.
Invenomic Capital Management's Bausch Health position peaked at $8.01M in Q4 2019.
327 funds tracked by Wall St. Rank held Bausch Health as of Q2 2022.

Based on Invenomic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.